At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 670 enrolled
Drug / intervention
Omadacycline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
In Brief
A Phase 3 clinical trial evaluating Omadacycline and Moxifloxacin for Community-acquired Pneumonia and Bacterial Pneumonia. Completed, enrolled 670 participants across 55 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-acquired Pneumonia, Bacterial Pneumonia
CountriesBulgaria, Croatia, Georgia, Hungary, Poland, Russia, Serbia, Ukraine
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartFeb 2021
First PostedMar 2021
Primary CompletionMar 2024
TodayJul 2026
First PostedMar 3, 2021
Enrollment StartFeb 25, 2021
Primary CompletionMar 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.3 years ago
Interventions
Omadacyclinedrug
IV for injection, oral tablets
Moxifloxacindrug
IV solution, oral tablets